Hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-19EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG
European Medicines Agency authorises Opdivo (nivolumab) for multiple cancer indications, including melanoma, non-small cell lung cancer, ren…
-
EMA approval · 2026-07-01EMA Authorised: Keytruda (pembrolizumab) — Merck Sharp & Dohme B.V.
EMA authorises Keytruda (pembrolizumab) for multiple cancer indications, including melanoma, Hodgkin disease, renal cell carcinoma, non-smal…
-
EMA approval · 2026-04-22EMA Authorised: Keytruda (pembrolizumab) — Merck Sharp & Dohme B.V.
The European Medicines Agency authorised Keytruda (pembrolizumab) for multiple cancer indications, including melanoma, Hodgkin lymphoma, ren…
-
EMA approval · 2026-03-20EMA Authorised: Adcetris (Brentuximab vedotin) — Takeda Pharma A/S
EMA authorised Adcetris (brentuximab vedotin) for Hodgkin lymphoma and non-Hodgkin lymphoma, with Takeda Pharma A/S as the marketing authori…
-
EMA approval · 2026-03-18EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG
EMA authorised Opdivo (nivolumab) for multiple cancer indications, including melanoma, Hodgkin lymphoma, renal cell carcinoma, non-small cel…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-10-27FDA Approved: LOMUSTINE — Original Application (Carnegie Pharmaceuticals LLC)
FDA approves Carnegie Pharmaceuticals LLC's original application for lomustine (LOMUSTINE), making a generic version of the chemotherapy dru…
-
EMA approval · 2025-06-18EMA Authorised: Phelinun (melphalan hydrochloride) — ADIENNE S.r.l. S.U.
The EMA authorised Phelinun (melphalan hydrochloride) for multiple cancers including multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphom…
-
FDA approval · 2024-12-26FDA Approved: CYCLOPHOSPHAMIDE — Original Application (Slate Run Pharmaceuticals, LLC)
FDA approves Slate Run Pharmaceuticals' original application for CYCLOPHOSPHAMIDE FOR INJECTION, expanding the market for a generic cyclopho…
-
EMA approval · 2024-09-03EMA Authorised: Carmustine medac (previously Carmustine Obvius) (carmustine) — medac Gesellschaft für klinische Spezialpräparate mbH
EMA authorised Carmustine medac (carmustine) for Hodgkin lymphoma and non-Hodgkin lymphoma; the marketing authorization holder is medac Gese…
-
FDA approval · 2021-04-30FDA Approved: CARMUSTINE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for Carmustine submitted by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. This actio…
-
FDA approval · 2021-01-14FDA Approved: VINCRISTINE SULFATE — Supplemental Application (Hospira, Inc.)
The FDA approved a supplemental application filed by Hospira for vincristine sulfate, a generic vincristine product.
-
FDA approval · 2018-10-16FDA Approved: CARMUSTINE — Original Application (Amneal Pharmaceuticals LLC)
FDA approved the original ANDA for Carmustine (BiCNU) submitted by Amneal Pharmaceuticals LLC.
-
FDA approval · 2018-09-28FDA Approved: BUSULFEX — Supplemental Application (Otsuka America Pharmaceutical, Inc.)
FDA approved a supplemental application for Busultex (busulfan) filed by Otsuka America Pharmaceutical, Inc. The action updates the labeling…
-
FDA approval · 2018-09-11FDA Approved: CARMUSTINE — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approved Carmustine as an original ANDA for Zydus Pharmaceuticals USA Inc., authorizing a generic Carmustine formulation. The drug is us…
-
FDA approval · 2017-11-03FDA Approved: DOXORUBICIN HYDROCHLORIDE — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for doxorubicin hydrochloride from BluePoint Laboratories, adding a new approved generic version of …
-
FDA approval · 2016-04-28FDA Approved: CARMUSTINE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
The FDA approved a supplemental application for Carmustine submitted by Heritage Pharmaceuticals Inc. (doing business as Avet Pharmaceutical…
-
FDA approval · 2016-02-02FDA Approved: MATULANE — Supplemental Application (Leadiant Biosciences, Inc.)
FDA approved a supplemental application for MATULANE (procarbazine hydrochloride) submitted by Leadiant Biosciences, Inc.
-
FDA approval · 2015-08-20FDA Approved: BLEOMYCIN — Supplemental Application (Hospira, Inc.)
FDA approved a supplemental application for Bleomycin submitted by Hospira, Inc., updating the product's indications or labeling.
-
FDA approval · 2014-11-05FDA Approved: DOXORUBICIN HYDROCHLORIDE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for doxorubicin hydrochloride (Fresenius Kabi USA, LLC) under anANDA to support its generic product.
-
FDA approval · 2014-10-25FDA Approved: CYCLOPHOSPHAMIDE — Supplemental Application (Civica, Inc.)
FDA approved a supplemental application for Civica, Inc. to market a generic cyclophosphamide product.
-
FDA approval · 2013-08-15FDA Approved: GLEOSTINE — Supplemental Application (NextSource Biotechnology, LLC)
The FDA approved a supplemental application for Gleostine (lomustine) submitted by NextSource Biotechnology, LLC.
-
FDA approval · 2013-06-17FDA Approved: CYCLOPHOSPHAMIDE — Supplemental Application (Civica, Inc.)
FDA approved a supplemental application for cyclophosphamide from Civica, Inc. under ANDA 040745.
-
FDA approval · 2013-02-04FDA Approved: DOXORUBICIN HYDROCHLORIDE — Original Application (BluePoint Laboratories)
FDA approved a generic doxorubicin hydrochloride product under Original Application for BluePoint Laboratories (ANDA 203263). This marks app…
-
FDA approval · 2011-08-19FDA Approved: ADCETRIS — Original Application (SEAGEN INC.)
FDA approved ADCETRIS (brentuximab vedotin) in its original application for CD30-expressing classical Hodgkin lymphoma and systemic anaplast…
-
FDA approval · 2011-08-19FDA Approved: ADCETRIS — Supplemental Application (SEAGEN INC.)
The FDA approved a supplemental application for ADCETRIS (brentuximab vedotin) submitted by Seagen Inc.